Effects of Sitagliptin on Pancreatic β Cell Function and Microangiopathy in Japanese Patients With Type 2 Diabetes Mellitus: Follow-Up for 4 Years

Hiromi Hamamotoa, d, Hiroyuki Okadab, Mitsuhiko Nodac

Abstract

Background: This study was aimed at investigating the effect of long-term sitagliptin treatment in improving the pancreatic β cell function and its influence on microangiopathy in patients with type 2 diabetes mellitus.

Methods: The study was designed as a retrospective analysis of the data of 27 patients with type 2 diabetes mellitus who did not have any evident reduction of the renal function and had received sitagliptin treatment for 4 years or longer. The fasting plasma C-peptide level corrected for the fasting blood glucose level (C-peptide index (CPI)), hemoglobin A1c (HbA1c) and body weight were determined every year during the 4-year period, and the status of retinopathy and nephropathy at the end of the fourth year of sitagliptin treatment was compared with the pre-treatment status.

Results: Both the HbA1c and body weight were significantly decreased by 6 months after the start of treatment. Thereafter, the HbA1c showed no further rise during the subsequent 4-year period, while the body weight continued to decrease over the 4-year period. No significant change of the CPI, as compared to the pre-treatment level (0.95 ± 0.49), was observed at any time during the follow-up. The retinopathy and nephropathy remained unchanged in severity in most cases; however, progression of retinopathy was seen in seven cases (29%) and that of nephropathy in three cases (11%).

Conclusions: Maintenance of good blood glucose control for 4 years by sitagliptin treatment allowed the pancreatic β cell function to be preserved. However, it was not possible to suppress progression of microangiopathy completely by treatment for a short period of 4 years.

Keywords: Sitagliptin; Pancreatic β cell function; Microangiopathy; Japanese patients; Type 2 diabetes mellitus

Introduction

In the treatment of type 2 diabetes mellitus, attempt to maintain the pancreatic β cell function is an important issue. According to the report of the UKPDS16 [1], pancreatic β cell function improves slightly 1 year after the start of treatment of type 2 diabetes mellitus with any of insulin, a sulfonylurea (SU) or a biguanide; however, the function begins to decrease from the second year onward, showing a 4% reduction annually. Similar results have also been reported in Japanese patients by Funakoshi et al [2]. After the clinical introduction of dipeptidyl peptidase-4 (DPP-4) inhibitors, Seck et al [3] reported preservation of the pancreatic β cell function until 2 years after the start of sitagliptin treatment, but there are no reports on longer-term outcomes or the outcomes in Japanese patients, who are known to have lower insulin-secreting potential than Western patients. Under such circumstances, we recently conducted a retrospective evaluation of changes in the pancreatic β cell function following sitagliptin treatment for a 4-year period through analysis of the C-peptide index (CPI), i.e. fasting serum C-peptide level corrected for the fasting blood glucose level.

Patients and Methods

Initially, using our department diabetes database, we conducted a chart review of type 2 diabetes mellitus patients who had received sitagliptin (MSD K.K. a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) treatment (50 mg/day) at our hospital for 4 years or longer with oral informed consent. The dosage was 50 mg once in the morning, which is the recommended dose for patients without renal impairment in Japan. Of the 119 patients who began to receive sitagliptin treatment between January 2010 and April 2011, the 86 patients who discontinued receiving treatment at our facility within 4 years after the start (for reasons of referral to other facilities (50), no effect (13), withdrawal (nine), drop-out (six), cancer (four), or death (four)) were excluded, and the data of the remaining 33 patients were extracted for this study. Of these 33 patients, four...
Effects of Sitagliptin on Pancreatic Beta Cell

Table 1. Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients, n</th>
<th>Age, years (mean ± SD)</th>
<th>Male, n (%)</th>
<th>Duration of diabetes, n (%)</th>
<th>BMI, kg/m² (mean ± SD)</th>
<th>HbA1c (%) (mean ± SD)</th>
<th>CPI (mean ± SD)</th>
<th>Diabetic retinopathy, n (%)</th>
<th>Diabetic nephropathy, n (%)</th>
<th>Diabetes treatment, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>27</td>
<td>63.3 ± 9.2</td>
<td>20 (74)</td>
<td>6 (16)</td>
<td>22.9 ± 3.0</td>
<td>7.2 ± 1.8</td>
<td>0.95 ± 0.49</td>
<td>NDR 15 (56)</td>
<td>Stage 1 19 (70)</td>
<td>None 19 (70)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9 (33)</td>
<td></td>
<td></td>
<td></td>
<td>SDR 8 (30)</td>
<td>Stage 2 7 (26)</td>
<td>Insulin 3 (11)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7 (26)</td>
<td></td>
<td></td>
<td></td>
<td>PPDR 2 (7)</td>
<td>Stage 3 1 (4)</td>
<td>Sulfonlureas 9 (33)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11 (42)</td>
<td></td>
<td></td>
<td></td>
<td>PDR 0 (0)</td>
<td>Stage 4 0 (0)</td>
<td>Glinides 13 (48)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Unknown 2 (7)</td>
<td></td>
<td></td>
<td></td>
<td>Unknown 2 (7)</td>
<td>Stage 1 19 (70)</td>
<td>Biguanides 7 (26)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thiazolidinediones 8 (30)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>α-Glucosidase inhibitors 14 (52)</td>
</tr>
</tbody>
</table>


Table 1 summarizes the background variables at the baseline (age, gender, body weight, duration of illness, microangiopathy, treatment received, and laboratory data).

No significant change of the CPI (mean ± SD) from the pre-treatment level was observed during the treatment for 4 years (0.88 ± 0.28 at 6 months, 0.90 ± 0.38 at 1 year, 0.89 ± 0.62 at 2 years, 0.93 ± 0.41 at 3 years, and 0.88 ± 0.33 at 4 years) (Fig. 1A). The HbA1c decreased significantly to 6.3% ± 0.5% at 6 months (P = 0.03), remaining low thereafter until 4 years (6.4% ± 0.5% at 1 year (P = 0.03), 6.4% ± 0.5% at 2 years (P = 0.04), 6.3% ± 0.4% at 3 years (P = 0.02), and 6.3% ± 0.4% at 4 years (P = 0.03)) (Fig. 1B). The body weight also showed significant decrease at 6 months to -1.1 ± 2.5 kg (P = 0.03) and continued to decrease thereafter until 4 years (-1.4 ± 2.9 kg at 1 year (P = 0.02), -1.6 ± 3.1 kg at 2 years (P = 0.01), -1.9 ± 3.5 kg at 3 years (P = 0.01), and -2.8 ± 4.3 kg at 4 years (P = 0.002)) (Fig. 1C).
Figure 1. Changes in CPI (A), HbA1c (B), and body weight (C) during the treatment for 4 years. (A) CPI showed no significant change from the pre-treatment level at any point of time after the start of sitagliptin treatment. (B) HbA1c decreased significantly at 6 months and remained reduced thereafter until 4 years. (C) Body weight decreased significantly at 6 months and continued to decrease thereafter until 4 years.
Table 2. Changes in Retinopathy and Nephropathy After the 4-Year Treatment Period

<table>
<thead>
<tr>
<th></th>
<th>A. Retinopathy (n = 24)</th>
<th>B. Nephropathy (n = 27)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Improve</td>
<td>1 (4)</td>
<td>4 (15)</td>
</tr>
<tr>
<td>No change</td>
<td>16 (67)</td>
<td>20 (74)</td>
</tr>
<tr>
<td>Worse</td>
<td>7 (29)</td>
<td>3 (11)</td>
</tr>
</tbody>
</table>

Data are n (%). Frequency of outcomes of retinopathy: no change > worse > improve (A). Frequency of outcomes of nephropathy: no change > improve > worse (B).

In the analysis of the changes in the stage of microangiopathy, the stage of nephropathy improved in four patients (14.8%), remained unchanged in 20 patients (74.1%), and worsened in three patients (11.1%) (Table 2A). Changes in the stage of retinopathy were analyzed in 24 patients, after excluding three patients without sufficient data, revealing improvement in one patient (4.2%), no change in 16 patients (66.7%) and progression in seven patients (29.2%). Thus, retinopathy advanced more frequently than nephropathy (Table 2B).

Discussion

Sitagliptin has been shown in rats to suppress the expression of mediator proteins involved in the apoptotic machinery and inflammation, and to stimulate the expression of mediator proteins involved in angiogenesis/proliferation [4]. This drug is expected to also increase the pancreatic β cell population in humans. Based on these previous reports, we anticipated at the start of this study that the β cell function would improve year after year following the start of sitagliptin treatment. In practice, however, the function remained unchanged, although it did not decrease, resembling the results of the 2-year study reported by Seck et al [3]. This result is probably attributable to the relatively short treatment period, namely, the 4-year treatment was probably insufficient for the pancreatic β cell function-improving effect of this drug to be manifested in humans, although the effect in rats was observed just 6 weeks after the start of treatment. Notwithstanding this result, the pancreatic β cell function was maintained, without showing deterioration, during the 4-year treatment period. This suggests the possibility that the drug depressed the collapse of the β cell function indirectly through inducing good control of the blood glucose for a long term. These results from this study may be valuable in view of the previous report that good blood glucose control can be expected just by preservation of the pancreatic β cell function, even without improvement of the function [5].

In regard to microangiopathy, the disease stage advanced in some cases despite preservation of the pancreatic β cell function and good control of the HbA1c. Considering the report of Lachin et al [6] that while the fasting CPI was not correlated with the outcomes of diabetic complications, the post-prandial or post-glucagon load C-peptide level was correlated with the risk of occurrence of complications, it seems likely that the post-prandial CPI decreased over time in our patients who showed progression of microangiopathy. If post-prandial CPI decrease is absent, the progression of microangiopathy may be attributable to an insufficient length of the survey period in the present study as compared to past studies (7 years for the evaluation of complications in the diabetes control and complications trial (DCCT)/the epidemiology of diabetes interventions and complications (EDIC) [6]; 6 years [1] plus an additional 10 years [7] in the UKPDS) or attributable to the negative legacy effect of the previous poor control period [7].

The present study, which was designed as a retrospective survey, has limitations. Firstly, we did not prepare appropriate control patients since we extracted only patients who had received sitagliptin. It is unclear whether differences exist or not between patients with sitagliptin and others. Secondly, many patients dropped out of the study because of good control of blood glucose levels, resulting in referral to other facilities. If these patients had been followed up until the end of the study, different results might have been obtained. Thirdly, this study includes eight patients who had some changes in insulin secretagogue other than sitagliptin. Therefore, C-peptide values might have been influenced when insulin secretagogue was added or discontinued or the dose was increased or decreased.

In conclusion, sitagliptin for a period of 4 years yielded good blood glucose control and allowed the pancreatic β cell function to be preserved, although progression of microangiopathy was not completely suppressed. Thus, sitagliptin is promising as a drug for the treatment of type 2 diabetes mellitus.

Acknowledgement

The authors would like to thank Dr. Koji Nakanishi, for his advice. Mitsuhiko Noda has received speaker honoraria from Sanofi, Mitsubishi Tanabe Pharma, Daiichi Sankyo, Eli Lilly Japan, MSD, Sanwa Kagaku Kenkyusho, Ono Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, Astellas, Kowa Pharmaceutical Co. Ltd, Taisho Toyama Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co. Ltd, Meiji Seika Pharma Co. Ltd, Kyowa Hakko Kirin Co. Ltd, ABBVie Inc. and Johnson & Johnson K.K., and research grants from Takeda Pharmaceutical Co. Ltd, Daiichi Sankyo, Mitsubishi Tanabe Pharma and Kyowa Hakko Kirin Co. Ltd.

Grant Support

None.

References

1. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive dis-


